Condition: Functional Gastrointestinal Disorders · Sponsor: United Pharmaceuticals
This study aims to assess the evolution of functional gastrointestinal disorders (FGIDs) in infants fed with a new infant formula, using the Gastrointestinal (GI) and gastroesophageal reflux (GER) (GIGER) scale through an interventional, open-label, non-comparative multicenter study.
This description comes directly from the study's public registry record.
Anne-Sophie Garreau · 0033-155372222 · as.garreau@novalac.com
Caroline Thevret, Dr. · 0033-155372222 · c.thevret@novalac.com
Always discuss trial participation with your own doctor first.
| Site 02 | Nice, France | Not Yet Recruiting |
| Site 04 | Paris, France | Not Yet Recruiting |
| Site 03 | Toulon, France | Recruiting |
| Site 01 | Vincennes, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06488274